Pharmacologic doses of ascorbic acid and seleno-L-methionine are new and novel class of transforming growth factor-beta 1 inhibitor: mechanisms and therapeutic potential
Main Article Content
Abstract
TGF-?1, a multifunctional cytokine ubiquitously overexpressed in advanced cancers, is a critical target implicated in drug resistance, immune evasion, increased tumor angiogenesis, and unstable TME. We discovered for the first time that pharmacologic doses of SLM and AA are potent in vivo selective inhibitors of TGF-?1. Inhibition of TGF-?1 was associated with time-dependent inhibition of HIFs, PD-L1, VEGF, CAR-T cell activation, activation of TET by AA, inhibition of DNMTs by SLM, stabilization of tumor vasculature, increased drug delivery to tumor cells, and enhanced efficacy of oncolytic agents. The pleiotropic effects induced by pharmacologic doses and schedule of SLM offer the potential for enhancing the therapeutic efficacy of immunotherapy in cancer patients.
Article Details
How to Cite
M RUSTUM, Youcef et al.
Pharmacologic doses of ascorbic acid and seleno-L-methionine are new and novel class of transforming growth factor-beta 1 inhibitor: mechanisms and therapeutic potential.
Medical Research Archives, [S.l.], v. 14, n. 6, july 2026.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/7688>. Date accessed: 10 july 2026.
doi: https://doi.org/10.18103/mra.2026.0326.
Keywords
Clear cell renal cell carcinoma, non-small cell lung cancer, transforming growth factor-beta1, seleno-L-methionine, ascorbic acid, DNA methylation
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.